Kailera to present Phase 3 ribupatide trial designs at ObesityWeek 2026
KLRA•Kailera Therapeutics will present Phase 3 ribupatide trial designs at ObesityWeek 2026, while Hengrui Pharma will present Phase 3 HARBOR-1 findings for oral safiglipron.
1. Conference presentations
Kailera Therapeutics will present designs for the KaiNETIC-1, KaiNETIC-2 and KaiNETIC-3 Phase 3 trials evaluating ribupatide in people with obesity on November 15 at ObesityWeek 2026, held November 14-17 in Washington, D.C. Research scheduled for November 16 will examine real-world obesity medication management and unmet clinical needs among adults with severe obesity. Hengrui Pharma will present Phase 3 HARBOR-1 findings for oral safiglipron on November 15; Kailera holds development rights outside Greater China.
